New data released today in CDC’s MMWR show that nirsevimab, a long-acting monoclonal antibody product, was highly effective in protecting infants from hospitalizations associated with respiratory syncytial virus (RSV).
WordPress database error: [Table 'acdlpb3_wp339.wpe5_wpsecure_login' doesn't exist]SHOW COLUMNS FROM wpe5_wpsecure_login LIKE "country"
WordPress database error: [Table 'acdlpb3_wp339.wpe5_wpsecure_login' doesn't exist]ALTER TABLE wpe5_wpsecure_login ADD country VARCHAR(150)
WordPress database error: [Table 'acdlpb3_wp339.wpe5_wpsecure_login' doesn't exist]ALTER TABLE wpe5_wpsecure_login ADD city VARCHAR(100)